Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC）

Official record

Identifier

NCT06910072

Recruiting locations

country

China

Interventions studied

paclitaxel polymeric micelles + carboplatin + iparomilimab and tuvonralimab

Lead sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target enrolment

32 participants

Study type

INTERVENTIONAL

Phase

Phase 2/3

Status

Enrolling by invitation

First posted

Apr 4, 2025

Last updated on the registry

Aug 18, 2026

Age

18 Years – 75 Years

Sex

FEMALE

Study contact

No public contact is listed on the official record.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Triple-negative breast cancer
* The diameter of the primary tumor must be greater than 2cm, and the clinical stage should be II-III
* There is sufficient primary organ function
* The ECOG (PS) score is 0 or 1
* Expected survival ≥ 6 months
* The serum pregnancy test was negative. Use highly effective methods of contraception during the study period and for 180 days after the last dose of the study drug, and do not breastfeed

Exclusion Criteria:

* Bilateral breast cancer
* There is a history of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS)
* A history of invasive or metastatic breast cancer
* Any malignancy diagnosed within 5 years, excluding cured cervical carcinoma in situ, skin basal cell carcinoma, or squamous cell carcinoma
* There is an immune deficiency disease
* The presence of any autoimmune disease that still requires treatment or a history of prior autoimmune disease

Indexed under

Breast Cancer